Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
Launched by ST. ANTONIUS HOSPITAL · Apr 18, 2017
Trial Information
Current as of June 29, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient has provided written informed consent.
- • 2. Patient is undergoing TAVI.
- • 3. Patient has an estimated GFR \<60ml/min/1.73m2.
- Exclusion Criteria:
- • 1. Patient has end-stage kidney disease requiring dialysis.
- • 2. Emergent TAVI (planned before next working day).
- • 3. Recent exposure to radiographic contrast agents (within 2 days prior to the TAVI).
- • 4. Allergy to contrast agent.
- • 5. Planned administration of dopamine, mannitol, fenoldopam or N-acetylcysteine during the intended time of the study.
- • 6. Need for continuous hydration therapy (e.g. sepsis).
- • 7. Multiple myeloma.
- • 8. Contra-indication to sodium bicarbonate.
About St. Antonius Hospital
St. Antonius Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a strong emphasis on collaboration, the hospital brings together a multidisciplinary team of experts to conduct high-quality research across various therapeutic areas. Committed to ethical standards and patient safety, St. Antonius Hospital aims to contribute to the development of new treatments and therapies that enhance the quality of care for its diverse patient population. Through its robust clinical trial program, the hospital seeks to translate scientific discoveries into tangible health benefits.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nieuwegein, Utrecht, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials